Fresenius Medical Care Amends Humacyte Stake Filing

TL;DR

Fresenius updated their Humacyte filing on 11/18/24. Watch for ownership changes.

AI Summary

Fresenius Medical Care Holdings Inc. has amended its Schedule 13D filing regarding Humacyte, Inc. The filing, dated November 18, 2024, indicates a change in beneficial ownership. Fresenius Medical Care AG is listed as a group member in this filing.

Why It Matters

This amendment signals a potential shift in the ownership structure or strategy of Humacyte, Inc., which could impact its stock price and future business operations.

Risk Assessment

Risk Level: medium — Amendments to 13D filings can indicate significant changes in a major shareholder's intentions, potentially leading to volatility.

Key Players & Entities

• Fresenius Medical Care Holdings Inc /NY/ (company) — Filing party
• Humacyte, Inc. (company) — Subject company
• Fresenius Medical Care AG (company) — Group member

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• tm2428715d1_sc13da.htm (SC 13D/A) — 55KB
• 0001104659-24-120135.txt ( ) — 57KB

Identity

Item 2. Identity and Background

of the Schedule 13D is hereby amended as set forth below

Item 2 of the Schedule 13D is hereby amended as set forth below: Effective June 1, 2024, Dr. Jörg Häring assumed office as a member of the Management Board of FME AG, Global Head of Legal, Compliance and Human Resources, and Labor Relations Director. Schedule I to this Schedule 13D in the form annexed to this Schedule 13D (Amendment No 2), setting forth information with respect to the directors and officers of FMCH, the members of the Supervisory Board of FME AG and the members of the Management Board of FME AG, is hereby amended by adding Dr. Jörg Häring to the list of members of the FME AG Management Board. Dr. Häring is a citizen of Germany. Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended by

Item 5 of the Schedule 13D is hereby amended by the addition of the following information: On the date of this Schedule 13D (Amendment No. 3), the Filing Persons are the beneficial owners of 18,312,735 shares of the Issuer’s Common Stock. On October 7, 2024, the Issur completed a public offering of 5,681,820 shares of its Common Stock, and on November 15, 2024, the Issuer completed a public offering of 2,808,988 shares of its Common Stock. The increase in the total outstanding shares of the Issuer’s Common Stock resulting from these public offerings reduced the Filing Persons’ beneficial ownership of the Issuer’s Common Stock from 15.4% of such outstanding shares, as reported in the Filing Persons’ Schedule 13D (Amendment No. 2), to 14.2% of such outstanding shares. Such percentage beneficial ownership has been calculated with respect to 128,668,484 shares of Common Stock, outstanding, consisting of 125,859,496 shares outstanding on November 1, 2024, as shown on the cover page of the Issuer’s Report on Form 10-Q filed November 8, 2024 and 2,808,988 shares of Common Stock issued in the Issuer’ public offering on November 15, 2024. Such calculation excludes 5,681,820 shares underlying presently exercisable warrants to purchase Common Stock issued in the October public offering and 2,808,988 shares underlying presently exercisable warrants to purchase Common Stock issued in the November public offering. The change in the Filing Persons’ percentage beneficial ownership reported in this Schedule 13D (Amendment No. 3) resulted solely from the increase in the number of outstanding shares of Common Stock in the Issuer’s public offerings. Neither of the Filing Persons has disposed of or acquired any shares of the Issuer’s Common Stock subsequent to the filing of the initial Schedule 13D in September 2021. Signature After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief,

View Full Filing

View this SC 13D/A filing on SEC EDGAR